Pasar al contenido principal

CONTRIBUCION DE LOXL2 Y LOXL3 A LA PROGRESION TUMORAL Y LA METASTASIS

SAF2016-76504-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

EMT: Present and future in clinical oncology

  • Santamaría, Patricia G.
  • Moreno-Bueno, Gema
  • Portillo, Francisco
  • Cano, Amparo
Epithelial/mesenchymal transition (EMT) has emerged as a key regulator of metastasis by facilitating tumor cell invasion and dissemination to distant organs. Recent evidences support that the reverse mesenchymal/epithelial transition (MET) is required for metastatic outgrowth; moreover, the existence of hybrid epithelial/mesenchymal (E/M) phenotypes is increasingly being reported in different tumor contexts. The accumulated data strongly support that plasticity between epithelial and mesenchymal states underlies the dissemination and metastatic potential of carcinoma cells. However, the translation into the clinics of EMT and epithelial plasticity processes presents enormous challenges and still remains a controversial issue. In this review, we will evaluate current evidences for translational applicability of EMT and depict an overview of the most recent EMT in vivo models, EMT marker analyses in human samples as well as potential EMT therapeutic approaches and ongoing clinical trials. We foresee that standardized analyses of EMT markers in solid and liquid tumor biopsies in addition to innovative tools targeting the E/M states will become promising strategies for future translation to the clinical setting., Work in our laboratories is supported by grants from the Spanish Ministerio de Economía y Competitividad SAF2013-44739-R and SAF2016-76504-R (AC and FP), the Spanish Instituto de Salud Carlos III [RETIC-RD12/0036/0007, CIBERONC-CB16/12/00295 (AC); PI13/00132, PI16/00134 (GMB)] (all of them partly supported from EUFEDER funds), and Worldwide Cancer Research (WWCR, formerly AICR) WWCR 16-0295 (AC, PGS, and FP). PGS was funded by a postdoctoral contract from the Fundacion Científica AECC and presently from WWCR 16-0295., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl oxidase–like protein LOXL2 promotes lung metastasis of breast cancer

  • Salvador, Fernando
  • Martín, Alberto
  • López-Menéndez, Celia
  • Moreno-Bueno, Gema
  • Santos, Vanesa
  • Vázquez-Naharro, Alberto
  • Santamaría, Patricia G.
  • Morales, Saleta
  • Dubus, Pierre R.
  • Muinelo-Romay, Laura
  • López-López, Rafael
  • Tung, Jason C.
  • Weaver, Valerie M.
  • Portillo, Francisco
  • Cano, Amparo
The lysyl oxidase-like protein LOXL2 has been suggested to contribute to tumor progression and metastasis, but in vivo evidence has been lacking. Here we provide functional evidence that LOXL2 is a key driver of breast cancer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer. LOXL2 ablation in mammary tumor cells dramatically decreased lung metastasis, whereas LOXL2 overexpression promoted metastatic tumor growth. LOXL2 depletion or overexpression in tumor cells does not affect extracellular matrix stiffness or organization in primary and metastatic tumors, implying a function for LOXL2 independent of its conventional role in extracellular matrix remodeling. In support of this likelihood, cellular and molecular analyses revealed an association of LOXL2 action with elevated levels of the EMT regulatory transcription factor Snail1 and expression of several cytokines that promote premetastatic niche formation. Taken together, our findings established a pathophysiologic role and new function for LOXL2 in breast cancer metastasis., This work has been supported by grants from the Spanish Ministry of Economy and Innovation SAF2010-21143 (to A. Cano, F. Portillo), SAF2013-44739-R (to A. Cano, P.G. Santamaría, F. Portillo), SAF2016-76504-R (to A. Cano, C. Lopez-Menendez, P.G. Santamaría, F. Portillo), and CONSOLIDER-INGENIO 2010 CSD2007-00017 (to A. Cano), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 to A. Cano, G. Moreno-Bueno, P.G. Santamaria, F. Portillo and CIBERONC to A. Cano, G. Moreno-Bueno, F. Portillo, R. Lopez-Lopez, L. Muinelo-Romay, PI13/00132 to G. Moreno-Bueno (all partly supported by FEDER funds)]; Worldwide Cancer Research (formerly AICR) 12-1057 to A. Cano, A. Martin, P.G. Santamaría; Worldwide Cancer Research 16-0295 to A. Cano, F. Portillo, P.G. Santamaría; Comunidad de Madrid (S2010/BMD-2303 to A. Cano, G. Moreno-Bueno); AECC-2011 to G. Moreno-Bueno; and TV3-Telemarato 2013 to G. Moreno-Bueno. A. Martin, F. Salvador, and A. Vazquez-Naharro were funded by the JAE-CSIC program, S2010/BMD-2303, SAF2013-44739-R, and Worldwide Cancer Research 12-1057 grants; P.G. Santamaría by a contract from Fundacion AECC (Spain) and, presently, by Worldwide Cancer Research 16-0295 grant; V. Santos by CSD2007-00017, Worldwide Cancer Research 12-1057 and SAF2013-44739-R grants, and S. Morales by RETIC-RD12/0036/0007 grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

LOXL2 drives epithelialmesenchymal transition via activation of IRE1-XBP1 signalling pathway

  • Cuevas, Eva P.
  • Eraso, Pilar
  • Mazón, María J.
  • Santos, Vanesa
  • Moreno-Bueno, Gema
  • Cano, Amparo
  • Portillo, Francisco
Epithelial-to-Mesenchymal Transition (EMT) is a key process contributing to the aggressiveness of cancer cells. EMT is triggered by activation of different transcription factors collectively known as EMT-TFs. Different cellular cues and cell signalling networks activate EMT at transcriptional and posttranscriptional level in different biological and pathological situations. Among them, overexpression of LOXL2 (lysyl oxidase-like 2) induces EMT independent of its catalytic activity. Remarkably, perinuclear/cytoplasmic accumulation of LOXL2 is a poor prognosis marker of squamous cell carcinomas and is associated to basal breast cancer metastasis by mechanisms no yet fully understood. Here, we report that overexpression of LOXL2 promotes its accumulation in the Endoplasmic Reticulum where it interacts with HSPA5 leading to activation of the IRE1-XBP1 signalling pathway of the ER-stress response. LOXL2-dependent IRE1-XBP1 activation induces the expression of several EMT-TFs: SNAI1, SNAI2, ZEB2 and TCF3 that are direct transcriptional targets of XBP1. Remarkably, inhibition of IRE1 blocks LOXL2-dependent upregulation of EMT-TFs thus hindering EMT induction., This work has been supported by grants from the Spanish Ministerio de Economía y Competividad SAF2013-44739-R and SAF2016-76504-R (AC and FP), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 (AC), PI13/00132 (GMB), CB16/12/00295 (AC), CIBERONC (AC)] (all of them partly supported from EU-FEDER founds), and Worldwide Cancer Research (WWCR, formerly AICR) AICR 12-1057 (AC). EPC and VS were founded by postdoctoral and technician contracts, respectively, from SAF2013-44739-R and WWCR grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation

  • Kober, Katharina Isabelle
  • Cano, Amparo
  • Géraud, Cyrill
  • Sipilä, Kalle
  • Mobasseri, Seyedeh Atefeh
  • Philippeos, Christina
  • Oliveira Pisco, Angela
  • Stannard, Andrew
  • Martín, Alberto
  • Salvador, Fernando
  • Santos, Vanesa
  • Boutros, Michael
  • Rognoni, Emanuel
  • Watt, Fiona M.
Lysyl oxidase-like 2 (LOXL2) is a copper-dependent monoamine oxidase that contributes to the remodelling of the extracellular matrix (ECM) by cross linkage of collagen and elastin fibres and has emerged as a potential therapeutic target in cancer and fibrosis. In the skin, LOXL2 is essential for epidermal cell polarity and differentiation. However, its role in the dermis has not been evaluated. We found that Loxl2 is dispensable for mouse dermal development, maturation and homeostasis, yet affects dermal stiffness. Neither loss of Loxl2 nor increased Loxl2 expression affected dermal architecture following treatment with the phorbol ester TPA. Furthermore, Loxl2 expression did not alter the stroma of DMBA-TPA-induced tumours. We conclude that, although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis., F.M.W. gratefully acknowledges financial support from the Medical Research Council (G1100073), Cancer Research UK (C219/A23522) and the Wellcome Trust (096540/Z/11/Z). Research in A.C.’s lab is supported by the Spanish Ministry of Economy and Innovation (SAF2016-76504-R), Instituto de Salud Carlos III (RTICC: RD12/0036/0007 and CIBERONC: CB16/12/00295) and Worldwide Cancer Research (formerly AICR) (12-1057). E.R. is the recipient of an EMBO long-term fellowship (aALTF594-2014) and an EMBO Advanced Fellowship (aALTF 523-2017). K.S. is the recipient of a Finnish Cultural Foundation Fellowship. K.I.K. was supported by the Research Training Group RTG2099 “Hallmarks of Skin Cancer” of the German Research Foundation (Deutsche Forschungsgemeinschaft /DFG) GTK2099/RT2099, project 3 (M.B.). This work was supported in part by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft / DFG) GRK2099/ RTG2099, project 7 (C.G.). A.S. is supported by the Engineering and Physical Sciences Research Council (EP/K00641X/1 and EP/M022536/1). The authors would like to acknowledge the excellent support of the Nikon Imaging Centre at KCL and of the Light Microscopy Core Facility (Dr. F. Bestvater) at DKFZ. We also gratefully acknowledge the use of Core Facilities provided by the generous financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King’s College Hospital NHS Foundation Trust., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability

  • Santamaría, Patricia G.
  • Floristán, Alfredo
  • Fontanals-Cirera, Bárbara
  • Vázquez-Naharro, Alberto
  • Santos, Vanesa
  • Morales, Saleta
  • Yuste Pérez, Lourdes
  • Peinado, Héctor
  • García-Gómez, Antonio
  • Portillo, Francisco
  • Hernando, Eva
  • Cano, Amparo
Lysyl oxidase-like 3 (LOXL3) is a member of the lysyl oxidase family comprising multifunctional enzymes with depicted roles in extracellular matrix maturation, tumorigenesis, and metastasis. In silico expression analyses followed by experimental validation in a comprehensive cohort of human cell lines revealed a significant upregulation of LOXL3 in human melanoma. We show that LOXL3 silencing impairs cell proliferation and triggers apoptosis in various melanoma cell lines. Further supporting a pro-oncogenic role in melanoma, LOXL3 favors tumor growth in vivo and cooperates with oncogenic BRAF in melanocyte transformation. Upon LOXL3 depletion, melanoma cells display a faulty DNA damage response (DDR), characterized by ATM checkpoint activation and inefficient ATR activation leading to the accumulation of double-strand breaks (DSBs) and aberrant mitosis. Consistent with these findings, LOXL3 binds to proteins involved in the maintenance of genome integrity, in particular BRCA2 and MSH2, whose levels dramatically decrease upon LOXL3 depletion. Moreover, LOXL3 is required for efficient DSB repair in melanoma cells. Our results reveal an unexpected role for LOXL3 in the control of genome stability and melanoma progression, exposing its potential as a novel therapeutic target in malignant melanoma, a very aggressive condition yet in need for more effective treatment options., A.F.M. was supported by a FPI predoctoral fellowship from the Spanish Ministry of Economy and Innovation (MINECO) (associated to SAF2013-44739-R) and by Worldwide Cancer Research (16–0295) grant. P.G.S. was a recipient of an Oncology Research Contract (AIO) from the Fundación de la Asociación Española contra el Cáncer (AECC) and is currently funded by Worldwide Cancer Research (16–0295) grant. A.V-N., V.S., S.M., and L.Y. were supported by AICR, MINECO and the Spanish Fondo de Investigaciones Sanitarias (FIS). E.H.'s laboratory is funded by the NIH (US) (R01CA155234, R01CA163891, and R21AR062239). Work in the A.C.'s laboratory is supported by grants from the MINECO (SAF2013-44739-R, SAF2016-76504-R, ConsoliderIngenio ONCOBIO CSD00C-2007-00017), Comunidad de Madrid (S2010/BMD-2303), ISCIII (RTICC-RD12/0036/0007, CIBERONCCB16/12/00295), all of them partly supported from EU-FEDER funds, and Worldwide Cancer Research UK (formerly AICR, 12-1057, and 16-0295 grants)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Lysyl oxidase-like 3 in melanoma progression

  • Bustos-Tauler, José
  • Vázquez-Naharro, Alberto
  • Yuste Pérez, Lourdes
  • Cano, Amparo
  • Santamaría, Patricia G.
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., SAF2013-44739R, SAF2016-76504-R Ministerio de Economía y Competitividad (MINECO), CB16/12/00295 CIBERONC, 16-0295 Worldwide Cancer Research (WWCR), Red de Cáncer RETIC-RD12/0036/0007 (Instituto de Salud Carlos III)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

UPR: An Upstream Signal to EMT Induction in Cancer

  • Santamaría, Patricia G.
  • Mazón, María J.
  • Eraso, Pilar
  • Portillo, Francisco
© 2019 by the authors., The endoplasmic reticulum (ER) is the organelle where newly synthesized proteins enter the secretory pathway. Different physiological and pathological conditions may perturb the secretory capacity of cells and lead to the accumulation of misfolded and unfolded proteins. To relieve the produced stress, cells evoke an adaptive signalling network, the unfolded protein response (UPR), aimed at recovering protein homeostasis. Tumour cells must confront intrinsic and extrinsic pressures during cancer progression that produce a proteostasis imbalance and ER stress. To overcome this situation, tumour cells activate the UPR as a pro-survival mechanism. UPR activation has been documented in most types of human tumours and accumulating evidence supports a crucial role for UPR in the establishment, progression, metastasis and chemoresistance of tumours as well as its involvement in the acquisition of other hallmarks of cancer. In this review, we will analyse the role of UPR in cancer development highlighting the ability of tumours to exploit UPR signalling to promote epithelial-mesenchymal transition (EMT)., This research was funded by the Spanish Ministerio de Economía y Competitividad (MICINN) (SAF2013-44739-R and SAF2016-76504-R, EU-FEDER funds), Instituto de Salud Carlos III (CIBERONC 16/12/00295, EU-FEDER funds), and Worldwide Cancer Research (AICR-12-1057 and WWCR-16-0295).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

G‐protein‐coupled receptor kinase 2 safeguards epithelial phenotype in head and neck squamous cell carcinomas

  • Palacios-García, Julia
  • Sanz-Flores, María
  • Asensio, Alejandro
  • Alvarado, Raul
  • Rojo-Berciano, Susana
  • Stamatakis, Konstantinos
  • Paramio, Jesús M.
  • Cano, Amparo
  • Nieto, M. Ángela
  • García-Escudero, Ramón
  • Mayor Jr., Federico
  • Ribas, Catalina
Head and neck squamous cell carcinoma (HNSCC) arises from the mucosal lining of the upper aerodigestive tract and display few treatment options in advanced stages. Despite increased knowledge of HNSCC molecular biology, the identification of new players involved in triggering HNSCC recurrence and metastatic disease is needed. We uncover that G‐protein‐coupled receptor kinase‐2 (GRK2) expression is reduced in undifferentiated, high‐grade human HNSCC tumors, whereas its silencing in model human HNSCC cells is sufficient to trigger epithelial‐to‐mesenchymal transition (EMT) phenotypic features, an EMT‐like transcriptional program and enhanced lymph node colonization from orthotopic tongue tumors in mice. Conversely, enhancing GRK2 expression counteracts mesenchymal cells traits by mechanisms involving phosphorylation and decreased functionality of the key EMT inducer Snail1. Our results suggest that GRK2 safeguards the epithelial phenotype, whereas its downregulation contributes to the activation of EMT programs in HNSCC., Our laboratories are supported by Agencia Estatal de Investigación of Spain (grants SAF2014‐55511‐R and SAF2017‐84125‐R to F.M.; SAF2015‐66015‐R and ISCIII PIE15/00081 to J.P.M.; SAF2016‐76504‐R to A.C. and BFU2014‐53128‐R to M.A.N.); CIBERCV‐Instituto de Salud Carlos III, Spain (grant CB16/11/00278 to F.M., co‐funded with European FEDER contribution), CIBERONC‐Instituto de Salud Carlos III (grant CB16/12/00228 and CB16/12/00295 to J.M.P. and A.C., respectively, co‐funded with European FEDER contribution); Instituto de Salud Carlos III, Spain (grant PI14/00201 and PI18/01662 to C.R.; PI18/00263 to R.G.E., co‐funded with European FEDER contribution) and Fundación Ramón Areces (to C.R and F.M.), Swiss National Science Foundation (grant 144637, 153099), Swiss Cancer League (grant KLS 3243‐08‐2013) and Fundacion Anemia de Fanconi (grant 2018/127) to R.G.E.; and Programa de Actividades en Biomedicina de la Comunidad de Madrid‐B2017/BMD‐3671‐INFLAMUNE to F.M. M.S.F. was recipient of a Postdoctoral fellowship from Comunidad de Madrid (PEFD‐2017‐POST/BMD‐4442) and A.A. holds a PhD Fellowship from FPI programme Agencia Estatal de Investigación (PRE2018‐084418). We also acknowledge institutional support to the CBMSO from Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loxl3 promotes melanoma progression and dissemination influencing cell plasticity and survival

  • Vázquez-Naharro, Alberto
  • Bustos-Tauler, José
  • Floristán, Alfredo
  • Yuste Pérez, Lourdes
  • Oltra, Sara S.
  • Vinyals, Antònia
  • Moreno-Bueno, Gema
  • Fabra, Àngels
  • Portillo, Francisco
  • Cano, Amparo
  • Santamaría, Patricia G.
Malignant melanoma is a highly aggressive tumor causing most skin cancer-related deaths. Understanding the fundamental mechanisms responsible for melanoma progression and therapeutic evasion is still an unmet need for melanoma patients. Progression of skin melanoma and its dissemination to local or distant organs relies on phenotypic plasticity of melanoma cells, orchestrated by EMT-TFs and microphthalmia-associated TF (MITF). Recently, melanoma phenotypic switching has been proposed to uphold context-dependent intermediate cell states benefitting malignancy. LOXL3 (lysyl oxidase-like 3) promotes EMT and has a key role in human melanoma cell survival and maintenance of genomic integrity. To further understand the role of Loxl3 in melanoma, we generated a conditional Loxl3-knockout (KO) melanoma mouse model in the context of BrafV600E-activating mutation and Pten loss. Melanocyte-Loxl3 deletion increased melanoma latency, decreased tumor growth, and reduced lymph node metastatic dissemination. Complementary in vitro and in vivo studies in mouse melanoma cells confirmed Loxl3’s contribution to melanoma progression and metastasis, in part by modulating phenotypic switching through Snail1 and Prrx1 EMT-TFs. Importantly, a novel LOXL3-SNAIL1-PRRX1 axis was identified in human melanoma, plausibly relevant to melanoma cellular plasticity. These data reinforced the value of LOXL3 as a therapeutic target in melanoma., This research was funded by grants from the Spanish Ministry of Science and Innovation MCIN (SAF2016-76504-R to A.C. and F.P., PID2019-111052RB-100 to F.P., and PID2019–104644RBI00 to G.M.-B.), Instituto de Salud Carlos III (CIBERONC-CB16/12/00295 to A.C. and G.M.-B.), all of them partly supported by EU-FEDER funds, Worldwide Cancer Research UK (grant ref. 16-0295 to A.C., F.P., and P.G.S.), and FC AECC (Grupos Estables de Investigación 2018-AECC and PROYE19036MOR to G.M.-B., and 2015-AECC to À.F., GCB15152978SOEN). S.S.O. was supported by a 2019 AECC postdoctoral contract. A.V.-N. was supported by a FPI predoctoral fellowship from MCIN (BES-2017-081082). J.B.-T. was supported by a FPI fellowship associated with SAF2013-44739-R (A.C. and F.P.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loxl2 and Loxl3 Paralogues Play Redundant Roles during Mouse Development

  • Santamaría, Patricia G.
  • Dubus, Pierre R.
  • Bustos-Tauler, José
  • Floristán, Alfredo
  • Vázquez-Naharro, Alberto
  • Morales, Saleta
  • Cano, Amparo
  • Portillo, Francisco
Lysyl oxidase-like 2 (LOXL2) and 3 (LOXL3) are members of the lysyl oxidase family of enzymes involved in the maturation of the extracellular matrix. Both enzymes share a highly conserved catalytic domain, but it is unclear whether they perform redundant functions in vivo. In this study, we show that mice lacking Loxl3 exhibit perinatal lethality and abnormal skeletal development. Additionally, analysis of the genotype of embryos carrying double knockout of Loxl2 and Loxl3 genes suggests that both enzymes have overlapping functions during mouse development. Furthermore, we also show that ubiquitous expression of Loxl2 suppresses the lethality associated with Loxl3 knockout mice., This research was funded by grants from the Spanish Ministry of Science and Innovation MCIN SAF2016-76504-R (to A.C. and F.P.), PID2019-111052RB-100 (to F.P.) and from the Spanish Institute of Health Carlos III CIBERONC CCB16/12/00295 (to A.C.), all of them partly supported from EU-FEDER funds, and Worldwide Cancer Research (16–0295 to A.C., F.P. and P.G.S.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

  • Alonso-Nocelo, Marta
  • Ruiz-Cañas, Laura
  • Sancho, Patricia
  • Alcalá, Sonia
  • Pedrero García, Coral
  • Vallespinós, Mireia
  • López-Gil, Juan Carlos
  • Ochando, Marina
  • García-García, Elena
  • Trabulo, Sara María David
  • Martinelli, Paola
  • Sánchez-Tomero, Patricia
  • Sánchez-Palomo, Carmen
  • González-Santamaría, Patricia
  • Yuste Pérez, Lourdes
  • Wörmann, Sonja M.
  • Kabacaoglu, Derya
  • Earl, Julie
  • Martín, Alberto
  • Salvador, Fernando
  • Valle, Sandra
  • Martin-Hijano, Laura
  • Carrato, Alfredo
  • Erkan, Mert M.
  • García-Bermejo, María Laura
  • Hermann, Patrick C.
  • Algül, Hana
  • Moreno-Bueno, Gema
  • Heeschen, Christopher
  • Portillo, Francisco
  • Cano, Amparo
  • Sainz, Bruno Jr.
[Objective]: The lysyl oxidase-like protein 2 (LOXL2) contributes to tumour progression and metastasis in different tumour entities, but its role in pancreatic ductal adenocarcinoma (PDAC) has not been evaluated in immunocompetent in vivo PDAC models., [Design]: Towards this end, we used PDAC patient data sets, patient-derived xenograft in vivo and in vitro models, and four conditional genetically-engineered mouse models (GEMMS) to dissect the role of LOXL2 in PDAC. For GEMM-based studies, K-Ras +/LSL-G12D;Trp53 LSL-R172H;Pdx1-Cre mice (KPC) and the K-Ras +/LSL-G12D;Pdx1-Cre mice (KC) were crossed with Loxl2 allele floxed mice (Loxl2Exon2 fl/fl) or conditional Loxl2 overexpressing mice (R26Loxl2 KI/KI) to generate KPCL2KO or KCL2KO and KPCL2KI or KCL2KI mice, which were used to study overall survival; tumour incidence, burden and differentiation; metastases; epithelial to mesenchymal transition (EMT); stemness and extracellular collagen matrix (ECM) organisation., [Results]: Using these PDAC mouse models, we show that while Loxl2 ablation had little effect on primary tumour development and growth, its loss significantly decreased metastasis and increased overall survival. We attribute this effect to non-cell autonomous factors, primarily ECM remodelling. Loxl2 overexpression, on the other hand, promoted primary and metastatic tumour growth and decreased overall survival, which could be linked to increased EMT and stemness. We also identified tumour-associated macrophage-secreted oncostatin M (OSM) as an inducer of LOXL2 expression, and show that targeting macrophages in vivo affects Osm and Loxl2 expression and collagen fibre alignment., [Conclusion]: Taken together, our findings establish novel pathophysiological roles and functions for LOXL2 in PDAC, which could be potentially exploited to treat metastatic disease., JCL-G received support from a 'la Caixa' Foundation (ID 100010434) fellowship (LCF/BQ/DR21/11880011). This study was supported by ISCIII FIS grants PI18/00757 and PI21/01110 (BSJ) and PI18/00267 (LG-B), and grants from the Spanish Ministry of Economy and Innovation SAF2016-76504-R (ACan and FP), PID2019-111052RB-I00 (FP), PID2019-104644RB-I00 (GM-B), a Ramón y Cajal Merit Award RYC-2012–12104 (BSJ) and ISCIII, CIBERONC, CB16/12/00446 (ACar) and CB16/12/00295 (ACan and GM-B), all of them co-financed through Fondo Europeo de Desarrollo Regional (FEDER) 'Una manera de hacer Europa'; a Fero Foundation Grant (BSJ); a Coordinated grant (GC16173694BARB) from the Fundación Científica Asociación Española Contra el Cáncer (FC-AECC) (BSJ); a Miguel Servet award (CP16/00121) (PS); a DFG, German Research Foundation Grant—Project no: 492 436 553 (KG); and a Max Eder Fellowship of the German Cancer Aid (111746) (PCH)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New Functions of Intracellular LOXL2: Modulation of RNA-Binding Proteins

  • Eraso, Pilar
  • Mazón, María J.
  • Jiménez, Victoria
  • Pizarro-García, Patricia
  • Cuevas, Eva P.
  • Majuelos-Melguizo, Jara
  • Morillo-Bernal, Jesús
  • Cano, Amparo
  • Portillo, Francisco
Lysyl oxidase-like 2 (LOXL2) was initially described as an extracellular enzyme involved in extracellular matrix remodeling. Nevertheless, numerous recent reports have implicated intracellular LOXL2 in a wide variety of processes that impact on gene transcription, development, differentiation, proliferation, migration, cell adhesion, and angiogenesis, suggesting multiple different functions for this protein. In addition, increasing knowledge about LOXL2 points to a role in several types of human cancer. Moreover, LOXL2 is able to induce the epithelial-to-mesenchymal transition (EMT) process—the first step in the metastatic cascade. To uncover the underlying mechanisms of the great variety of functions of intracellular LOXL2, we carried out an analysis of LOXL2’s nuclear interactome. This study reveals the interaction of LOXL2 with numerous RNA-binding proteins (RBPs) involved in several aspects of RNA metabolism. Gene expression profile analysis of cells silenced for LOXL2, combined with in silico identification of RBPs’ targets, points to six RBPs as candidates to be substrates of LOXL2’s action, and that deserve a more mechanistic analysis in the future. The results presented here allow us to hypothesize novel LOXL2 functions that might help to comprehend its multifaceted role in the tumorigenic process., This research was funded by grants from the Spanish Ministry of Science and Innovation MCIN (SAF2016-76504-R to A.C. and F.P., PID2019-111052RB-I00 to F.P.) and the Instituto de Salud Carlos III (CIBERONC-CB16/12/00295 to A.C.), all of which were partially supported by EU-FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

LOXL2 in Cancer: A Two-Decade Perspective

  • Cano, Amparo
  • Eraso, Pilar
  • Mazón, María J.
  • Portillo, Francisco
Lysyl Oxidase Like 2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises five lysine tyrosylquinone (LTQ)-dependent copper amine oxidases in humans. In 2003, LOXL2 was first identified as a promoter of tumour progression and, over the course of two decades, numerous studies have firmly established its involvement in multiple cancers. Extensive research with large cohorts of human tumour samples has demonstrated that dysregulated LOXL2 expression is strongly associated with poor prognosis in patients. Moreover, investigations have revealed the association of LOXL2 with various targets affecting diverse aspects of tumour progression. Additionally, the discovery of a complex network of signalling factors acting at the transcriptional, post-transcriptional, and post-translational levels has provided insights into the mechanisms underlying the aberrant expression of LOXL2 in tumours. Furthermore, the development of genetically modified mouse models with silenced or overexpressed LOXL2 has enabled in-depth exploration of its in vivo role in various cancer models. Given the significant role of LOXL2 in numerous cancers, extensive efforts are underway to identify specific inhibitors that could potentially improve patient prognosis. In this review, we aim to provide a comprehensive overview of two decades of research on the role of LOXL2 in cancer., This research was funded by grants from the Spanish Ministry of Science and Innovation MCIN (SAF2016-76504-R to A.C. and F.P., PID2019-111052RB-I00 to F.P.) and the Instituto de Salud Carlos III (CIBERONC-CB16/12/00295 to A.C.), all of which were partially supported by EU-FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HuR (ELAVL1) Stabilizes SOX9 mRNA and Promotes Migration and Invasion in Breast Cancer Cells

  • Morillo-Bernal, Jesús
  • Pizarro-García, Patricia
  • Moreno-Bueno, Gema
  • Cano, Amparo
  • Mazón, María J.
  • Eraso, Pilar
  • Portillo, Francisco
RNA-binding proteins play diverse roles in cancer, influencing various facets of the disease, including proliferation, apoptosis, angiogenesis, senescence, invasion, epithelial–mesenchymal transition (EMT), and metastasis. HuR, a known RBP, is recognized for stabilizing mRNAs containing AU-rich elements (AREs), although its complete repertoire of mRNA targets remains undefined. Through a bioinformatics analysis of the gene expression profile of the Hs578T basal-like triple-negative breast cancer cell line with silenced HuR, we have identified SOX9 as a potential HuR-regulated target. SOX9 is a transcription factor involved in promoting EMT, metastasis, survival, and the maintenance of cancer stem cells (CSCs) in triple-negative breast cancer. Ribonucleoprotein immunoprecipitation assays confirm a direct interaction between HuR and SOX9 mRNA. The half-life of SOX9 mRNA and the levels of SOX9 protein decreased in cells lacking HuR. Cells silenced for HuR exhibit reduced migration and invasion compared to control cells, a phenotype similar to that described for SOX9-silenced cells, This research was funded by grants from the Spanish Ministry of Science and Innovation SAF2016-76504-R (A.C. and F.P.), PID2019-111052RB-100 (F.P.) and PID2019-104644RB-I00 (G.M.-B.) all of them partly supported by EU-FEDER funds., Peer reviewed